<DOC>
	<DOCNO>NCT00412997</DOCNO>
	<brief_summary>The phase I study evaluate safety , efficacy pharmacokinetics LBH589B adult patient advance solid tumor Cutaneous T-cell lymphoma</brief_summary>
	<brief_title>LBH589 Adult Patients With Advanced Solid Tumors Cutaneous T-cell Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<criteria>Patients either ) histologicallyconfirmed , advance solid tumor whose disease progress despite standard therapy standard therapy exist , b ) cytopathologically confirm cutaneous Tcell lymphoma ( CTCL ) whose disease progress despite standard therapy standard therapy exist . Inclusion irrespective stage disease extent prior therapy . World Health Organization ( WHO ) Performance Status ≤ 2 Patients must adequate laboratory value Patients history primary CNS tumor Patients history brain metastases Patients peripheral neuropathy ≥ CTCAE grade 2 Patients unresolved diarrhea ≥ CTCAE grade 2 Impairment cardiac function Impairment gastrointestinal ( GI ) function GI disease Liver renal disease Other protocoldefined inclusion/exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>advanced solid tumor</keyword>
	<keyword>Cutaneous T-cell lymphoma</keyword>
	<keyword>Phase I</keyword>
	<keyword>HDAC inhibitor</keyword>
	<keyword>Adult patient</keyword>
</DOC>